These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
558 related articles for article (PubMed ID: 9381986)
1. Regulation of carrier-mediated transport of folates and antifolates in methotrexate-sensitive and-resistant leukemia cells. Jansen G; Mauritz RM; Assaraf YG; Sprecher H; Drori S; Kathmann I; Westerhof GR; Priest DG; Bunni M; Pinedo HM; Schornagel JH; Peters GJ Adv Enzyme Regul; 1997; 37():59-76. PubMed ID: 9381986 [TBL] [Abstract][Full Text] [Related]
2. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. Jansen G; Mauritz R; Drori S; Sprecher H; Kathmann I; Bunni M; Priest DG; Noordhuis P; Schornagel JH; Pinedo HM; Peters GJ; Assaraf YG J Biol Chem; 1998 Nov; 273(46):30189-98. PubMed ID: 9804775 [TBL] [Abstract][Full Text] [Related]
3. Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis. Mauritz R; Peters GJ; Priest DG; Assaraf YG; Drori S; Kathmann I; Noordhuis P; Bunni MA; Rosowsky A; Schornagel JH; Pinedo HM; Jansen G Biochem Pharmacol; 2002 Jan; 63(2):105-15. PubMed ID: 11841783 [TBL] [Abstract][Full Text] [Related]
4. Variable expression of RFC1 in human leukemia cell lines resistant to antifolates. Kobayashi H; Takemura Y; Ohnuma T Cancer Lett; 1998 Feb; 124(2):135-42. PubMed ID: 9500202 [TBL] [Abstract][Full Text] [Related]
5. Methotrexate transport in variant human CCRF-CEM leukemia cells with elevated levels of the reduced folate carrier. Selective effect on carrier-mediated transport of physiological concentrations of reduced folates. Jansen G; Westerhof GR; Jarmuszewski MJ; Kathmann I; Rijksen G; Schornagel JH J Biol Chem; 1990 Oct; 265(30):18272-7. PubMed ID: 2211701 [TBL] [Abstract][Full Text] [Related]
6. Clustering of mutations in the first transmembrane domain of the human reduced folate carrier in GW1843U89-resistant leukemia cells with impaired antifolate transport and augmented folate uptake. Drori S; Jansen G; Mauritz R; Peters GJ; Assaraf YG J Biol Chem; 2000 Oct; 275(40):30855-63. PubMed ID: 10899164 [TBL] [Abstract][Full Text] [Related]
7. Functional activity of the reduced folate carrier in KB, MA104, and IGROV-I cells expressing folate-binding protein. Westerhof GR; Rijnboutt S; Schornagel JH; Pinedo HM; Peters GJ; Jansen G Cancer Res; 1995 Sep; 55(17):3795-802. PubMed ID: 7641196 [TBL] [Abstract][Full Text] [Related]
8. Cytotoxicity of trimetrexate against antifolate-resistant human T-cell leukemia cell lines developed in oxidized or reduced folate. Miyachi H; Takemura Y; Kobayashi H; Ando Y Jpn J Cancer Res; 1997 Sep; 88(9):900-6. PubMed ID: 9369939 [TBL] [Abstract][Full Text] [Related]
9. Identification of a membrane-associated folate-binding protein in human leukemic CCRF-CEM cells with transport-related methotrexate resistance. Jansen G; Westerhof GR; Kathmann I; Rademaker BC; Rijksen G; Schornagel JH Cancer Res; 1989 May; 49(9):2455-9. PubMed ID: 2706633 [TBL] [Abstract][Full Text] [Related]
10. 5-amino-4-imidazolecarboxamide riboside potentiates both transport of reduced folates and antifolates by the human reduced folate carrier and their subsequent metabolism. McGuire JJ; Haile WH; Yeh CC Cancer Res; 2006 Apr; 66(7):3836-44. PubMed ID: 16585211 [TBL] [Abstract][Full Text] [Related]
11. Impact of polyglutamation on sensitivity to raltitrexed and methotrexate in relation to drug-induced inhibition of de novo thymidylate and purine biosynthesis in CCRF-CEM cell lines. Barnes MJ; Estlin EJ; Taylor GA; Aherne GW; Hardcastle A; McGuire JJ; Calvete JA; Lunec J; Pearson AD; Newell DR Clin Cancer Res; 1999 Sep; 5(9):2548-58. PubMed ID: 10499632 [TBL] [Abstract][Full Text] [Related]
12. Multiple membrane transport systems for the uptake of folate-based thymidylate synthase inhibitors. Jansen G; Schornagel JH; Westerhof GR; Rijksen G; Newell DR; Jackman AL Cancer Res; 1990 Dec; 50(23):7544-8. PubMed ID: 2253202 [TBL] [Abstract][Full Text] [Related]
13. 5,10-Dideazatetrahydrofolic acid (DDATHF) transport in CCRF-CEM and MA104 cell lines. Pizzorno G; Cashmore AR; Moroson BA; Cross AD; Smith AK; Marling-Cason M; Kamen BA; Beardsley GP J Biol Chem; 1993 Jan; 268(2):1017-23. PubMed ID: 8419310 [TBL] [Abstract][Full Text] [Related]
14. Molecular events in the membrane transport of methotrexate in human CCRF-CEM leukemia cell lines. Freisheim JH; Ratnam M; McAlinden TP; Prasad KM; Williams FE; Westerhof GR; Schornagel JH; Jansen G Adv Enzyme Regul; 1992; 32():17-31. PubMed ID: 1323203 [TBL] [Abstract][Full Text] [Related]
15. Folate transport and the modulation of antifolate sensitivity in a methotrexate-resistant human breast cancer cell line. Dixon KH; Trepel JB; Eng SC; Cowan KH Cancer Commun; 1991; 3(12):357-65. PubMed ID: 16296001 [TBL] [Abstract][Full Text] [Related]
16. Loss of multidrug resistance protein 1 expression and folate efflux activity results in a highly concentrative folate transport in human leukemia cells. Assaraf YG; Rothem L; Hooijberg JH; Stark M; Ifergan I; Kathmann I; Dijkmans BA; Peters GJ; Jansen G J Biol Chem; 2003 Feb; 278(9):6680-6. PubMed ID: 12486126 [TBL] [Abstract][Full Text] [Related]
17. Determinants of the disparate antitumor activities of (6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate and methotrexate toward human lymphoblastic leukemia cells, characterized by severely impaired antifolate membrane transport. Matherly LH; Angeles SM; McGuire JJ Biochem Pharmacol; 1993 Dec; 46(12):2185-95. PubMed ID: 7506026 [TBL] [Abstract][Full Text] [Related]
18. Large diversity in transport-mediated methotrexate resistance in human leukemia cell line CCRF-CEM established in a high concentration of leucovorin. Asai S; Miyachi H; Kobayashi H; Takemura Y; Ando Y Cancer Sci; 2003 Feb; 94(2):210-4. PubMed ID: 12708499 [TBL] [Abstract][Full Text] [Related]
19. Functional aspects of membrane folate receptors in human breast cancer cells with transport-related resistance to methotrexate. Pinard MF; Jolivet J; Ratnam M; Kathmann I; Molthoff C; Westerhof R; Schornagel JH; Jansen G Cancer Chemother Pharmacol; 1996; 38(3):281-8. PubMed ID: 8646804 [TBL] [Abstract][Full Text] [Related]